Business Context and Reporting Period
This Form 8-K filing by LABCORP HOLDINGS INC. reports a corporate governance event. The date of the earliest event reported is February 6, 2026, with the report signed on February 9, 2026.
Key Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the appointment of a new director to the Board of Directors:
- Appointee: John H. Sampson, M.D., Ph.D.
- Effective Date: February 9, 2026.
- Committee Assignment: Quality and Compliance Committee.
- Background: Dr. Sampson is the vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine. He previously held senior leadership roles at Duke University Health System and is a practicing neurosurgeon.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The appointment is subject to compensation consistent with the Company's director compensation program as described in the proxy statement filed on April 4, 2025.
Investor Verification Checklist
- Verify Dr. Sampson's full biographical details and potential conflicts of interest via the attached press release (Exhibit 99.1).
- Review the Company's most recent proxy statement (filed April 4, 2025) to confirm the specific compensation structure for new directors.
- Confirm the effective date of the appointment (February 9, 2026) against the Board meeting minutes if available.